PXS Share Price

Open 0.27 Change Price %
High 0.27 1 Day -0.01 -3.70
Low 0.26 1 Week -0.01 -3.70
Close 0.26 1 Month -0.02 -7.14
Volume 196458 1 Year 0.02 8.33
52 Week High 0.34
52 Week Low 0.24
PXS Important Levels
Resistance 2 0.27
Resistance 1 0.27
Pivot 0.26
Support 1 0.25
Support 2 0.25
ASX Australia Most Active Stocks
BUR 0.02 0.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
AGO 0.03 0.00%
AGO 0.03 0.00%
AGO 0.03 0.00%
KEY 0.01 0.00%
KEY 0.01 0.00%
KEY 0.01 0.00%
KEY 0.01 0.00%
More..
ASX Australia Top Gainers Stocks
KSO 0.40 3900.00%
IRM 0.03 50.00%
IRM 0.03 50.00%
IRM 0.03 50.00%
GBG 0.03 50.00%
GBG 0.03 50.00%
GBG 0.03 50.00%
BNV 0.03 50.00%
PMQ 0.03 50.00%
ANP 0.04 33.33%
More..
ASX Australia Top Losers Stocks
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
TCQ 0.27 -73.53%
XST 0.01 -50.00%
XST 0.01 -50.00%
GDY 0.01 -50.00%
RDS 0.02 -33.33%
RDS 0.02 -33.33%
More..

Pharmaxis Ltd (ASX: PXS)

PXS Technical Analysis 4
As on 24th Mar 2017 PXS Share Price closed @ 0.26 and we RECOMMEND Sell for LONG-TERM with Stoploss of 0.27 & Strong Sell for SHORT-TERM with Stoploss of 0.28 we also expect STOCK to react on Following IMPORTANT LEVELS.
PXS Target for March
1st Target up-side 0.3
2nd Target up-side 0.31
3rd Target up-side 0.32
1st Target down-side 0.26
2nd Target down-side 0.25
3rd Target down-side 0.24
PXS Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.pharmaxis.com.au
PXS Address
PXS
20 Rodborough Road
Frenchs Forest, NSW 2086
Australia
Phone: 61 2 9454 7200
Fax: 61 2 9451 3622
PXS Latest News
Interactive Technical Analysis Chart Pharmaxis Ltd ( PXS ASX Australia )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Pharmaxis Ltd
PXS Business Profile
Pharmaxis Ltd, a pharmaceutical company, is engaged in the research, development, and commercialization of human healthcare products for the treatment and management of respiratory diseases in Australia, European Union, Korea, and the United States. The company’s commercial product includes Aridol, a lung function test designed to assist doctors diagnose and manage asthma by detecting active airway inflammation through measuring airway hyper-responsiveness. Its principal product in the development comprises Bronchitol, a drug designed to reduce the amount of mucus build-up in the lungs of patients suffering from chronic respiratory conditions, including cystic fibrosis, bronchiectasis, and chronic bronchitis. Bronchitol is approved for the treatment of cystic fibrosis in adults and pediatric patients in Australia and European Union. The company’s early product development pipeline includes orbital dry powder inhaler that delivers drug doses to the lungs; LOXL-2 inhibitors for the treatment of fibrosis; PXS-4728A–novel SSAO/VAP-1 inhibitor for the treatment of chronic lung inflammation; PXS64/25 targeting lung fibrosis; ASM8 targeting severe asthma; and PXS TPI1100 for the treatment candidate for COPD. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.